CN106834196A - Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared - Google Patents
Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared Download PDFInfo
- Publication number
- CN106834196A CN106834196A CN201710228755.0A CN201710228755A CN106834196A CN 106834196 A CN106834196 A CN 106834196A CN 201710228755 A CN201710228755 A CN 201710228755A CN 106834196 A CN106834196 A CN 106834196A
- Authority
- CN
- China
- Prior art keywords
- content
- reduced
- serum
- diabetes mellitus
- lactobacillus plantarum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 82
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 82
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 82
- 235000013305 food Nutrition 0.000 title claims abstract description 21
- 150000004676 glycans Chemical class 0.000 title abstract description 6
- 229920001282 polysaccharide Polymers 0.000 title abstract description 6
- 239000005017 polysaccharide Substances 0.000 title abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 85
- 230000000694 effects Effects 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 33
- 239000008280 blood Substances 0.000 claims abstract description 33
- 150000002632 lipids Chemical class 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 210000002966 serum Anatomy 0.000 claims description 79
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 235000000346 sugar Nutrition 0.000 claims description 19
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 16
- 239000002158 endotoxin Substances 0.000 claims description 16
- 102000004877 Insulin Human genes 0.000 claims description 15
- 108090001061 Insulin Proteins 0.000 claims description 15
- 229940125396 insulin Drugs 0.000 claims description 15
- 102000016938 Catalase Human genes 0.000 claims description 13
- 108010053835 Catalase Proteins 0.000 claims description 13
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 13
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 13
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 12
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 12
- 230000037356 lipid metabolism Effects 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 235000021588 free fatty acids Nutrition 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 abstract description 13
- 238000004321 preservation Methods 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 239000002068 microbial inoculum Substances 0.000 abstract description 3
- 235000013618 yogurt Nutrition 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 40
- 239000000243 solution Substances 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 238000012360 testing method Methods 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 210000000941 bile Anatomy 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000288673 Chiroptera Species 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- -1 thiazole Alkane Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DBOVHQOUSDWAPQ-UHFFFAOYSA-N (4aS)-6c-[O2-(3,5,3'-trihydroxy-biphenyl-2-carbonyl)-beta-D-glucopyranosyloxy]-5t-vinyl-(4ar)-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-1-one Natural products OC1C(O)C(CO)OC(OC2C(C3C(C(OCC3)=O)=CO2)C=C)C1OC(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-UHFFFAOYSA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 1
- IZSRJDGCGRAUAR-MROZADKFSA-M 5-dehydro-D-gluconate Chemical class OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IZSRJDGCGRAUAR-MROZADKFSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BZXINCMCFVKGKB-UHFFFAOYSA-N Amarogentin Natural products OCC1OC(OC2OC=C3C(CCOC3=O)C2C=C)C(OC(=O)c4cc(O)cc(O)c4c5cccc(O)c5)C(O)C1O BZXINCMCFVKGKB-UHFFFAOYSA-N 0.000 description 1
- PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- KVZLHPXEUGJPAH-QRLADXQJSA-N C([C@H](O)C)(=O)O.C([C@H](O)C)(=O)O Chemical compound C([C@H](O)C)(=O)O.C([C@H](O)C)(=O)O KVZLHPXEUGJPAH-QRLADXQJSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000169594 Paropsia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000009651 Voges-Proskauer test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- DBOVHQOUSDWAPQ-WTONXPSSSA-N amarogentin Chemical compound O([C@H]1[C@H](O[C@H]2[C@@H]([C@H]3C(C(OCC3)=O)=CO2)C=C)O[C@@H]([C@H]([C@@H]1O)O)CO)C(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-WTONXPSSSA-N 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 238000009654 indole test Methods 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005293 physical law Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000008494 α-glucosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Abstract
The invention discloses Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared.Lactobacillus plantarum (Lactobacillus plantarum) CH126 that the present invention is provided, preservation registration number is CGMCC NO.13228, abbreviation Lactobacillus plantarum CH126.The present invention also applications of the protection Lactobacillus plantarum CH126 in product is prepared.The product is food, health products or medicine.The food concretely functional food, such as functional yoghourt, feature microbial inoculum etc..The function of the product is：Hypoglycemic and/or reducing blood lipid；Treatment and/or prevention diabetes.Lactobacillus plantarum CH126 has strong reduction fasting blood-glucose, effect for reducing blood fat, can be with being widely used in food, health food and medical and health field.
Description
Technical field
The present invention relates to Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared.
Background technology
Diabetes (Diabetes Mellitus, DM) are a kind of common chronic metabolic diseases, are often accompanied by artery athero-
The complication such as hardening, ephrosis, DPN, PVR.Diabetes B patient itself can not effectively utilize insulin or shape
Into insulin resistant, causing the glucose utilization rate of insulin-mediated reduces, and then causes the generations such as internal sugar, fat, protein
It is unrest to thank.Clinically the medicine of anti-diabetic has the agent of promotion insulin secretion, biguanides, alpha-glucosidase restrainer, thiazole
Alkane diones etc., the long-term taking serious side effect such as paropsia, gastrointestinal dysfunction, hepatic and renal function can be caused impaired.
Therefore, hypoglycemic method that is safe and reliable, having no side effect is found, more there is realistic meaning.
Probiotics is the probiotics of the work for having facilitation to host health.Probiotics be widely used to food,
The fields such as functional food, medicine.Probiotics is improving enteron aisle, enhance immunity, Reduce allergy reaction, regulation blood lipid metabolism, tune
The aspects such as section blood pressure play a significant role.Lactic acid bacteria is the superior microorganism species in some traditional fermented foods, is feature
The important sources of probiotics.
The content of the invention
It is an object of the invention to provide Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared.
Lactobacillus plantarum (Lactobacillus plantarum) CH126 that the present invention is provided, in November 01 in 2016
Day is preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center, and (abbreviation CGMCC, address is：Court of Beijing
The institute 3 of positive area's North Star West Road 1, Institute of Microorganism, Academia Sinica), preservation registration number is CGMCCNO.13228.Plant breast
Bacillus (Lactobacillus plantarum) CH126CGMCC NO.13228, abbreviation Lactobacillus plantarum CH126.
The present invention also applications of the protection Lactobacillus plantarum CH126 in product is prepared.The product be food, health products or
Medicine.The food concretely functional food, such as functional yoghourt, feature microbial inoculum etc..The function of the product is
At least one in (a1) to (a31) as follows：(a1) hypoglycemic and/or reducing blood lipid；(a2) blood-sugar content in serum is reduced；
(a3) lipids contents in serum are reduced；(a4) total cholesterol level in serum is reduced；(a5) glycerine three in serum is reduced
Ester content；(a6) fasting blood sugar is reduced；(a7) oxidation resistance is increased；(a8) superoxide dismutase in serum is increased
Content and/or activity；(a9) content and/or activity of the catalase in serum are increased；(a10) the paddy Guang in serum is increased
The content and/or activity of sweet peptide peroxidase；(a11) content and/or activity of the MDA in serum are reduced；(a12) change
Kind disorders of lipid metabolism；(a13) the D-ALPHA-Hydroxypropionic acid content in serum is reduced；(a14) free fatty acid content in serum is reduced；
(a15) endotoxin content in serum is reduced；(a16) treat and/or prevention diabetes；(a17) Diabetes Mellitus are reduced
In blood-sugar content；(a18) lipids contents in Diabetes Mellitus are reduced；(a19) in reduction Diabetes Mellitus
Total cholesterol level；(a20) content of triglyceride in Diabetes Mellitus is reduced；(a21) sky of diabetic is reduced
Abdomen blood glucose value；(a22) insulin content in Diabetes Mellitus is raised；(a23) increase super in Diabetes Mellitus
The content and/or activity of superoxide dismutase；(a24) increase catalase in Diabetes Mellitus content and/or
Activity；(a25) content and/or activity of the glutathione peroxidase in Diabetes Mellitus are increased；(a26) sugar is reduced
The content and/or activity of the MDA in urine patient's serum；(a27) disorders of lipid metabolism of diabetic is improved；(a28)
Reduce the D-ALPHA-Hydroxypropionic acid content in Diabetes Mellitus；(a29) free fatty acid content in Diabetes Mellitus is reduced；
(a30) endotoxin content in Diabetes Mellitus is reduced；(a31) hyperlipidemic conditions of diabetic are improved.
The present invention also protects a kind of product, and its active component is Lactobacillus plantarum CH126.The present invention also protects a kind of producing
Product, its active component is the extract of the fermentate of the fermentate or Lactobacillus plantarum CH126 of Lactobacillus plantarum CH126.It is described
Product is food, health products or medicine.The food concretely functional food, such as functional yoghourt, feature microbial inoculum
Deng.The function of the product is at least one in following (a1) to (a31)：(a1) hypoglycemic and/or reducing blood lipid；(a2) reduce
Blood-sugar content in serum；(a3) lipids contents in serum are reduced；(a4) total cholesterol level in serum is reduced；(a5) drop
Content of triglyceride in low serum；(a6) fasting blood sugar is reduced；(a7) oxidation resistance is increased；(a8) in increasing serum
The content and/or activity of superoxide dismutase；(a9) content and/or activity of the catalase in serum are increased；(a10)
Increase the content and/or activity of the glutathione peroxidase in serum；(a11) content of the MDA in serum is reduced
And/or activity；(a12) disorders of lipid metabolism is improved；(a13) the D-ALPHA-Hydroxypropionic acid content in serum is reduced；(a14) in reduction serum
Free fatty acid content；(a15) endotoxin content in serum is reduced；(a16) treat and/or prevention diabetes；(a17) reduce
Blood-sugar content in Diabetes Mellitus；(a18) lipids contents in Diabetes Mellitus are reduced；(a19) glycosuria is reduced
Total cholesterol level in patient's serum；(a20) content of triglyceride in Diabetes Mellitus is reduced；(a21) reduce
The fasting blood sugar of diabetic；(a22) insulin content in Diabetes Mellitus is raised；(a23) diabetes are increased
The content and/or activity of the superoxide dismutase in patients serum；(a24) hydrogen peroxide in Diabetes Mellitus is increased
The content and/or activity of enzyme；(a25) content and/or the work of glutathione peroxidase in Diabetes Mellitus are increased
Property；(a26) content and/or activity of the MDA in Diabetes Mellitus are reduced；(a27) lipid of diabetic is improved
Metabolic disorder；(a28) the D-ALPHA-Hydroxypropionic acid content in Diabetes Mellitus is reduced；(a29) trip in Diabetes Mellitus is reduced
From content of fatty acid；(a30) endotoxin content in Diabetes Mellitus is reduced；(a31) blood high of diabetic is improved
Fat symptom.
The concretely diabetes B of diabetes described in any of the above.
Lactobacillus of the invention is that the one plant of hypoglycemic work(for obtaining is screened from the lactic acid bacteria of numerous traditional fermented foods source
Can probiotics new strains, its not only have very strong reduction fasting blood-glucose, effect for reducing blood fat, also with good tolerance,
Good hydrophobicity and self-coagulation ability, there are different sensitiveness to different antibiotic, safety, and without toxicity, side effect, can use
It is widely used in food, health food and medical and health field.
Brief description of the drawings
Fig. 1 is the testing result of serum insulin
Specific embodiment
Following embodiment facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method, unless otherwise specified, is conventional method.Test material used in following embodiments, unless otherwise specified, is certainly
What routine biochemistry reagent shop was commercially available.Quantitative test in following examples, is respectively provided with three repetitions and tests, and as a result makes even
Average.
Unless otherwise specified, the PBS in embodiment is the PBS of pH7,0.1M.
Solid BCP culture mediums：2.5g/L containing yeast extract, peptone 5g/L, glucose 5g/L, bromocresol purple 0.04g/L, fine jade
Fat 15g/L, balance of water；Unless otherwise specified, pH=7.0.Liquid B CP culture mediums only exist with the difference of solid BCP culture mediums
In being added without agar.
Solid MRS culture mediums：10g/L containing peptone, beef extract 10g/L, yeast extract 5g/L, KH2PO42g/L, sodium acetate
5g/L, sodium citrate 5g/L, MgSO4·7H2O 0.2g/L、MnSO4·4H2O 0.05g/L, Tween-80 1mL/L, agar
15g/L, glucose 20g/L, balance of water；Unless otherwise specified, pH=6.6.Liquid MRS culture mediums and solid MRS culture mediums
Differ only in and be added without agar.
Basal feed：This experimental animal technology Co., Ltd of Changchun hundred million.High lipid food (% represents g/100g)：Base
Plinth feed 75%, lard 10%, yolk powder 10%, cholesterol (food-grade, Zhengzhou Cang Yu chemical products Co., Ltd) 5%.
C57BL/6J mouse：Changchun hundred million this experimental animal technology Co., Ltd, animal credit number：SCXK (Ji) -2011-
0004。
Using the T-CHOL in mouse T-CHOL enzyme linked immunological kit (BPE20095) the detection serum of bright of Shanghai
(Total Cholesterol, TC) content.Examined using bright of Shanghai mouse triglycerides enzyme linked immunological kit (BPE20754)
Triglycerides (Triglyceride, the TG) content surveyed in serum.Using bright of Shanghai mouse HDL-C enzyme
Linked immunoassay reagent kit (BPE20192) detection serum in HDL-C (High DensityLipoprotein,
HDL-C) content.Using bright of Shanghai mouse LDL-C enzyme linked immunological kit (BPE20100) detection serum
In LDL-C (Low Density Lipoprotein, LDL-C) content.Using bright of Shanghai mouse pancreas
Insulin (Insulin, INS) content in island element enzyme linked immunological kit (BPE20353) detection serum.Using bright of Shanghai
Mouse glutathione peroxidase immune reagent kit (BPE20748) detects serum Glutathione Peroxidase
The content of (Glutathione peroxidase, GSH-Px).Using bright of Shanghai mouse superoxide dismutase immune reagent kit
(BPE20348) content of superoxide dismutase (Superoxidedismutase, SOD) in serum is detected.Using Shang Hailang
Mouse hydrogen peroxide Enzymoimmune reagent kit (BPE20880) that pauses detects the content of catalase (Catalase, CAT) in serum.
Using MDA in bright mouse MDA immune reagent kit (BPE20347) in Shanghai detection serum (Malondialdehyde,
MDA content).Using free fatty in mouse free fatty immune reagent kit (BPE20248) the detection serum of bright of Shanghai
The content of (Free fat acid, FFA).Using bright of Shanghai Mouse endotoxin immune reagent kit (BPE20316) detection serum
The content of middle endotoxin (Endotoxin, ET).Using bright of Shanghai mouse D-ALPHA-Hydroxypropionic acid immune reagent kit (BPE20072) detection blood
The content of D-ALPHA-Hydroxypropionic acid (D-Lactate) in clear.
Lactobacillus plantarum (Lactobacillus plantarum) Sc52, was preserved in China on 06 29th, 2015
(abbreviation CGMCC, address is Microbiological Culture Collection administration committee common micro-organisms center：BeiChen West Road, Chaoyang District, BeiJing City 1
Number institute 3, Institute of Microorganism, Academia Sinica), preservation registration number is CGMCC NO.11027.Lactobacillus plantarum
(Lactobacillus plantarum) Sc52CGMCC NO.11027, abbreviation Lactobacillus plantarum Sc52.
Separation, identification and the preservation of embodiment 1, lactobacillus plantarum strain
First, the separation of lactobacillus plantarum strain
Sample is drawn materials：Traditional fermented food is vinegar-pepper radish.
Rule repeatedly culture through BCP culture medium flat plates, the single bacterium colony that picking produces yellow circle is inoculated in solid MRS culture medium flat plates
It is upper to continue to cultivate, rule repeatedly culture purified through solid MRS culture medium flat plates, obtain many plants of Pure cultured spawns.
The strain of pure culture is inoculated into liquid MRS medium cultures, is subsequently adding 20% glycerine, -80 DEG C of Refrigerator stores.
Filtered out from the strain of pure culture Gram-positive, catalase test is negative, indole reaction is negative,
Hydrogen sulfide production test is negative, gelatin liquefaction test is negative, hydrolysis starch negative and negative some of nitrate reduction test
Bacterial strain.It is CH126 by wherein 1 plant Strain Designation.
2nd, the identification of bacterial strain
The Physiology and biochemistry qualification result of CH126：Gram-positive, catalase test is negative, benzidine test
Feminine gender, indole test is negative, and voges-Proskauer test is positive；Not hydrolysis starch, do not liquefy gelatin, does not produce hydrogen sulfide, hair
Ferment glucose produces acid not aerogenesis；No motion of bacillus；Can be grown at 15 DEG C and 45 DEG C, 37~42 DEG C of optimum growth temperature；It is suitable
Suitable pH is 5.0~7.0；Tolerance 6.5%NaCl；CH126 is in uniform turbid growth in liquid MRS culture mediums, and being long placed in thalline is in
White precipitate.
API 50CH (French Mei Liai companies) qualification result of CH126：Ribose, galactolipin, glucose, fruit can be utilized
Sugar, xylose, mannose, mannitol, sorbierite, amarogentin, ursin, N- acetyl-gucosamine, seven leaf-alcohols, salicin, fiber
Disaccharides, synanthrin, lactose, melibiose, sucrose, trehalose, sorbose, melezitose, raffinose, geraniol, gluconate；No
Adonite, arabinose, glycogen, dulcitol, maltose, inositol, Alpha-Methyl-D-Glucose glycosides, Alpha-Methyl-D- sweet dews can be utilized
Glucosides, starch, rhamnose, xylitol, D- turanoses, D-Tag, D- meters of threose, gluconate, D-R alcohol, rock
Sugar, L-arabinose alcohol, 2- keto-D-gluconates salt, 5- keto-D-gluconate salt.
16S rDNA sequence homology analysis：Genomic DNA is extracted, the primer pair (16sF constituted using 16sF and 16sR：
5 ＇-AGAGTTTGATCCTGGCTCAG-3 ＇；16sR：5 ＇-AGAAAGGAGGTGATCCAGC-3 ＇) enter performing PCR amplification, then will
Amplified production is sequenced, and 16srDNA sequences are as shown in the sequence 1 of sequence table.16s rDNA sequences are existed by blast program
Sequence analysis analysis is carried out in GenBank storehouses, with Lactobacillus plantarum strain RI-113
(GenBank:CP017406.1) homology reaches 98%.
According to above qualification result, bacterial strain CH126 belongs to Lactobacillus plantarum.
3rd, the preservation of bacterial strain
Lactobacillus plantarum (Lactobacillus plantarum) CH126, is preserved in China on November 01st, 2016
(abbreviation CGMCC, address is Microbiological Culture Collection administration committee common micro-organisms center：BeiChen West Road, Chaoyang District, BeiJing City 1
Number institute 3, Institute of Microorganism, Academia Sinica), preservation registration number is CGMCC NO.13228.Lactobacillus plantarum
(Lactobacillus plantarum) CH126CGMCC NO.13228, abbreviation Lactobacillus plantarum CH126.
The functional characteristic of embodiment 2, Lactobacillus plantarum CH126
The method of colony counting, after completing culture, doubling dilution simultaneously coats solid MRS culture medium flat plates, 37 DEG C of standings
Colony counting is carried out after culture 48h.
First, acid-fast ability and bile tolerance ability
1st, acid-fast ability
The liquid MRS culture mediums that Lactobacillus plantarum CH126 or Lactobacillus plantarum Sc52 are inoculated in different pH (use 1mol/L salt
Acid adjust pH be respectively 2.0,3.0 or 6.6) in, 37 DEG C of quiescent cultures 1h or 3h, then by colony counting calculate bacteria concentration (use
Log10CFU/mL is represented).
Every kind of pH sets 3 parallel processing, and each dilution factor is once again set up 3 parallel processing, results averaged.
The results are shown in Table 1.Lactobacillus plantarum CH126：Strain growth is good under the conditions of pH6.6, extension viable bacteria over time
Number is in rising trend；Viable bacteria is not detected by after cultivating 3h under the conditions of pH2.0；Under the conditions of pH3.0, strains expressed has gone out certain resistance to
Acidity, survival rate is still 61.5% after culture 3h；Result shows that Lactobacillus plantarum CH126 has stronger sour tolerance.Plant
Lactobacillus Sc52：Under the conditions of pH3.0, survival rate is 57.0% after culture 3h.
Bacteria concentration (Logs of the Lactobacillus plantarum CH126 of table 1 in Liquid Culture system10CFU/mL)
2nd, bile tolerance ability
Lactobacillus plantarum CH126 or Lactobacillus plantarum Sc52 are inoculated in the liquid MRS culture mediums containing various concentrations bovine bile
(weight/mass percentage composition of bovine bile is respectively 0.3%, 0.5% or 1.0%), 37 DEG C of quiescent culture 4h, then by bacterium colony meter
Number calculates bacteria concentration and (uses Log10CFU/mL is represented).
Every kind of bovine bile concentration sets 3 parallel processing, and each dilution factor is once again set up 3 parallel processing, as a result makes even
Average.
The results are shown in Table 2.Lactobacillus plantarum CH126：Strain survival rate is 52% under 0.3% gallbladder salinity, in 0.5% courage
Strain survival rate is 46% under salinity, and Strain survival rate is 32% under 1% gallbladder salinity；Result shows, Lactobacillus plantarum
CH126 has stronger cholate tolerance.Lactobacillus plantarum Sc52：Strain survival rate is 49% under 0.3% gallbladder salinity,
Strain survival rate is 42% under 0.5% gallbladder salinity, and Strain survival rate is 25% under 1% gallbladder salinity.
Bacteria concentration (Logs of the Lactobacillus plantarum CH126 of table 2 in Liquid Culture system10CFU/mL)
| Initial bacteria concentration | 0.3% bovine bile | 0.5% bovine bile | 1.0% bovine bile | |
| Lactobacillus plantarum CH126 | 8.14±0.16 | 4.25±0.04 | 3.75±0.17 | 2.61±0.18 |
| Lactobacillus plantarum Sc52 | 8.16±0.31 | 4.00±0.15 | 3.41±0.13 | 2.07±0.09 |
2nd, the hydrophobicity of Lactobacillus plantarum CH126 and self-coagulation ability are determined
Bacterium surface hydrophobic effect and self-coagulation ability be somatic cells adhere to biological and inanimate surfaces it is important because
One of element.Physical law (bacterial adhesion substance, BATS) is sticked together using bacterium and determines Lactobacillus plantarum
The hydrophobicity of CH126.Self-solidifying rate is caused by bacterial strain surface hydrophobic, at the same it is closely related with its adhesive capacity, self-solidifying rate high
Bacterial strain typically has adhesive capacity higher.
1st, hydrophobicity
By the thalline of Lactobacillus plantarum CH126 brine 2 times, 0.1mol/L KNO are then used3The aqueous solution hangs
Floating thalline, it is 1 × 10 to obtain bacteria concentration8The bacterium solution of CFU/mL, determines the OD value A of bacterium solution at 600nm wavelength0.By 3mL bacterium
Liquid is mixed with 1mL organic solvents (dimethylbenzene, chloroform or ethyl acetate), is then stored at room temperature 30min, collects water phase, 600nm ripples
Strong point determines the OD value A of water phase1.Calculate hydrophobicity (BATS).Hydrophobic evaluation criterion is as follows：BATS>50% is height
Hydrophobicity, BATS is that moderate is hydrophobic in 20%-50%, BATS<20% is non-hydrophobic.Carry out three repetitions to test, even taking of finding an excuse
Average value.
The results are shown in Table 3.Lactobacillus plantarum CH126 shows non-hydrophobic ability in dimethylbenzene, ethyl acetate and chloroform.
The hydrophobicity (%) of the Lactobacillus plantarum CH126 of table 3
| Dimethylbenzene | Ethyl acetate | Chloroform |
| 17.0±0.90 | 5.0±0.24 | 18.7±1.52 |
2nd, self-coagulation ability
By the thalline of Lactobacillus plantarum CH126 brine 2 times, physiological saline suspension thalline is then used, obtained
Initial bacterium solution, determines the OD value A of initial bacterium solution at 600nm wavelength0It is 1.0.1mL is taken after initial bacterium solution is stored at room temperature into 1h
Upper phase, determines the OD value of bacterium solution at 600nm wavelength, be A1.Initial bacterium solution is stored at room temperature 1mL upper stratas are taken after 24h
Liquid phase, determines the OD value of bacterium solution at 600nm wavelength, be A2.Initial bacterium solution is stored at room temperature 1mL upper phases is taken after 48h,
The OD value of bacterium solution is determined at 600nm wavelength, is A3.Calculate self-solidifying rate (bacterial strain self-coagulation percentage).Carry out three repetitions
Experiment, even averaging of finding an excuse.
The results are shown in Table 4.Increase over time, Lactobacillus plantarum CH126 self-solidifyings rate is raised, upper phase is in clear after 48h
Clear state, self-solidifying rate reaches 84.2%.
The self-solidifying rate (%) of the Lactobacillus plantarum CH126 of table 4
| 1h | 24h | 48h |
| 2.5±0.4 | 75.3±0.57 | 84.2±1.00 |
3rd, antibiotic susceptibility test
1st, antibiotic is configured to the mother liquor that concentration is 5120 μ g/mL, with 0.22 μm of filter membrane mistake as solvent with distilled water
Bacterium is filtered, then stepwise dilution is carried out with sterilized water, following various antibiotic solutions are obtained：
Concentration is 0.016 μ g/mL, μ g/mL0.032 μ g/mL, 0.064 μ g/mL, 0.125 μ g/mL, 0.25 μ g/mL, 0.5 μ
The erythromycin solution of g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL or 8 μ g/mL；
Concentration be 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/mL, 32 μ g/mL, 64 μ g/mL,
The streptomycin sulfate solution of 128 μ g/mL or 256 μ g/mL；
Concentration be 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/mL, 32 μ g/mL, 64 μ g/mL,
The gentamycin solution of 128 μ g/mL or 256 μ g/mL；
Concentration be 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/mL, 32 μ g/mL, 64 μ g/mL, 128 μ g/mL, 256 μ g/mL,
The kanamycin sulfate solution of 512 μ g/mL or 1024 μ g/mL；
Concentration is 0.125 μ g/mL, 0.25 μ g/mL, 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/
The quadracycline solution of mL, 32 μ g/mL or 64 μ g/mL；
Concentration be 0.25 μ g/mL, 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/mL, 32 μ g/mL,
The vancomycin solution of 64 μ g/mL or 128 μ g/mL；
Concentration is 0.125 μ g/mL, 0.25 μ g/mL, 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/
The chloromycetin solution of mL, 32 μ g/mL, 64 μ g/mL or 128 μ g/mL；
Concentration is 0.032 μ g/mL, 0.063 μ g/mL, 0.125 μ g/mL, 0.25 μ g/mL, 0.5 μ g/mL, 1 μ g/mL, 2 μ g/
The ampicillin sodium solution of mL, 4 μ g/mL, 8 μ g/mL or 16 μ g/mL；
Concentration is 0.125 μ g/mL, 0.25 μ g/mL, 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/
The rifampin solution of mL, 32 μ g/mL or 64 μ g/mL；
Concentration is 0.125 μ g/mL, 0.25 μ g/mL, 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/
The trimethoprim solution of mL, 32 μ g/mL, 64 μ g/mL or 128 μ g/mL.
2nd, Lactobacillus plantarum CH126 dilutes 1000 times with liquid MRS culture mediums, and it is 1 × 10 to obtain bacteria concentration8CFU/mL's
Bacterium solution.
3rd, 96 orifice plates are taken, test hole adds antibiotic prepared by the bacterium solution and 70 μ L steps 1 of the preparation of 70 μ L steps 2 molten per hole
Liquid, Positive control wells add the bacterium solution and 70 μ L sterilized waters of 70 μ L steps 2 preparation per hole, and negative control hole adds 70 μ L liquid per hole
Body MRS culture mediums and 70 μ L sterilized waters, 37 DEG C of quiescent culture 16h, then observe the growing state of bacterial strain in 96 orifice plates, hence it is evident that nothing
Antibiotic concentration corresponding to the hole of strain growth is MIC of the antibiotic to bacterial strain.Each of every kind of antibiotic
Dilution factor sets 3 parallel processing.
The results are shown in Table 5.Lactobacillus plantarum CH126 is more sensitive to chloramphenicol, rifampin, penicillin, to vancomycin, card
That mycin shows strong drug resistance.
Minimum inhibitory concentrations (μ g/mL) of the Lactobacillus plantarum CH126 of table 5 to different antibiotic
4th, alpha-glucosaccharase enzyme inhibition is tested
1st, Lactobacillus plantarum CH126 thalline are taken, is suspended with PBS (pH6.8,0.1mol/L), it is 1 to obtain bacteria concentration
×109The bacterium solution of CFU/mL.
2nd, the bacterium solution of 50 μ L steps 1 preparation is taken, 100 μ L PBSs (pH6.8,0.1mol/L) are added, 100 are added
P-nitrophenyl-α-D- the glucopyranosides aqueous solution (PNPG solution) of μ L 20mmol/L, 37 DEG C of hatching 10min after mixing,
60 μ L 20U/mL alpha-glucosaccharase enzyme aqueous solutions are subsequently adding, then 37 DEG C of hatching 20min, are subsequently adding 100 μ L 1mol/L
Na2CO3Aqueous solution terminating reaction, the densitometric value at 405nm.
In formula：A contains bacterium solution and alpha-glucosaccharase enzyme aqueous solution for sample sets；B for sample sets contain bacterium solution without α-
Glucoside enzyme aqueous solution (is replaced) with isometric PBS；C is (slow with isometric PBS for blank control group does not contain bacterium solution
Fliud flushing replacement) enzyme aqueous solution containing alpha-glucosaccharase；D does not contain bacterium solution (being replaced with isometric PBS) for blank control group
Alpha-glucosaccharase enzyme aqueous solution (being replaced with isometric PBS) is not contained yet.
Lactobacillus plantarum CH126 is shown in Table 6 to alpha-glucosaccharase enzyme inhibition rate.Lactobacillus plantarum CH126 is to alpha-glucosaccharase
Enzyme shows certain inhibitory action, can improve the metabolism of glucose.
The Lactobacillus plantarum CH126 of table 6 is to alpha-glucosaccharase enzyme inhibition rate
| Bacterial strain | Inhibiting rate |
| CH126 | 29.35 ± 2.16% |
The adjustment effect of embodiment 3, Lactobacillus plantarum CH126 to blood sugar
First, packet transaction mode
80 male C 57 BL/6 J mouses, are randomly divided into 4 groups, and every group 20, packet transaction is as follows：
Blank control group：Fed using normal diet from on-test to end；9th week, mouse was on an empty stomach after 12 hours
Disposable celiac injecting normal saline 30mg/kg；It is administered within 10th week to the 13rd week, dosage is " every per kg body weight
It is secondary to give 12mL sterile PBS buffers "；
Model group：Fed with high lipid food within 1st week to 8 weeks, fed with normal diet within the 9th week to off-test；9th week,
Mouse empty stomach disposable intraperitoneal injection Streptozotocin 30mg/kg after 12 hours；It is administered within 10th week to the 13rd week；To medicament
Measure is " giving 12mL sterile PBS buffers every time per kg body weight "；
Positive controls：Fed with high lipid food within 1st week to 8 weeks, fed with normal diet within the 9th week to off-test；9th
Week, mouse empty stomach disposable intraperitoneal injection Streptozotocin 30mg/kg after 12 hours；It is administered within 10th week to the 13rd week；Give
Pharmaceutical quantities are for " it is (double containing 120mg diformazans in 12mL melbine solution that every kg body weight gives 12mL melbine solution every time
Guanidine；The solvent of melbine solution is PBS) "；
CH126 groups：Fed with high lipid food within 1st week to 8 weeks, fed with normal diet within the 9th week to off-test；9th week,
Mouse empty stomach disposable intraperitoneal injection Streptozotocin 30mg/kg after 12 hours；It is administered within 10th week to the 13rd week；To medicament
Measure " to give the 12mL bacterium solutions (preparation method of bacterium solution every time per kg body weight：With PBS suspension plant lactobacillus
CH126, it is 1.0 × 10 to obtain Lactobacillus plantarum CH126 concentration9The bacterium solution of CFU/mL) ".
Administering mode is：Gastric infusion, once a day.
Test within 1st week to 8 weeks the 1-56 days, be within the 10th week to 13 weeks experiment the 64-91 days, by that analogy.Note in abdominal cavity
Penetrate Streptozotocin or physiological saline is carried out on the 57th day in experiment.
2nd, judge to set up diabetes model standard
9th week (experiment the 63rd day), tail vein blood determines mouse fasting blood sugar (FBG).Meet the small of following standard
Mouse is diabetes B model mice：Double measure FBG >=11.1mmol/L.Result shows, tests the 57th day, model
Group, positive controls and CH126 groups each mouse are diabetes B model mice, and blank control group each mouse is sky
The orthoglycemic mouse of abdomen.
3rd, blood sugar test
Respectively at the 10th week, the 11st week, the 12nd week, the 13rd week and the 14th week, tail vein blood determined mouse fasting blood-glucose
Value (detection, calculates the average value in this week daily).
Fasting blood sugar the results are shown in Table 7.Compared with model group, CH126 group mouse fasting blood sugars are on a declining curve.
CH126 group mouse fasting blood sugars were remarkably decreased the 12nd week, the 13rd week, the 14th week, and blood glucose value is dropped at the 14th week
12.35mmol/L, there is pole significant difference (P ＜ 0.01) compared with model group mouse.Result shows, Lactobacillus plantarum CH126
There is therapeutic action to the hyperglycemia of diabetes B, fasting blood sugar can be significantly reduced.
Influences of the Lactobacillus plantarum CH126 of table 7 to diabetes B mouse fasting blood-glucose
Note：Compare with model group, * has significant difference (P ＜ 0.05), * * have pole significant difference (P ＜ 0.01).
4th, in serum index of correlation detection
During off-test (experiment the 100th day), each group mouse is taken, pluck eyeball and take blood, 3 000r/ after room temperature solidification 60min
Min is centrifuged 15min, collects supernatant (serum).Detection serum in T-CHOL, triglycerides, HDL-C,
LDL-C, insulin, glutathione peroxidase, superoxide dismutase, catalase, the third two
Aldehyde, free fatty, endotoxin, the content of D-ALPHA-Hydroxypropionic acid.
The testing result of blood fat correlation factor is shown in Table 8 in serum.TC, TG, LDL-C content are bright in model group mice serum
Aobvious is higher than blank control group, and HDL-C contents are significantly lower than blank control group, and this is because diabetes cause Mice Body intracellular metabolite disorderly
Disorderly.Compared with model group, TC, TG, LDL-C content decline in CH126 group mice serums.Result shows, Lactobacillus plantarum CH126
The hyperlipidemic conditions of diabetes B can be obviously improved.
Influences of the Lactobacillus plantarum CH126 of table 8 to diabetes B lipid of mice
Note：Compare with model group, * has significant difference (P ＜ 0.05), * * have pole significant difference (P ＜ 0.01).
The testing result of serum insulin is shown in Fig. 1.Sugar environment high suppresses glucose stimulated insulin secreting function, causes
Serum insulin content declines, and gavage Lactobacillus plantarum CH126 can effectively alleviate internal metabolic disorder, controls blood sugar, improves pancreas
Island function, improves serum insulin content (P ＜ 0.05).
The testing result of anti-oxidant correlation factor is shown in Table 9 in serum.The peroxide injury that diabetes B causes causes model
Anti-oxidant vigor declines in group mice serum, SODs of the mouse gavaging Lactobacillus plantarum CH126 after 4 weeks in mice serum, CAT,
GSH-Px vigor is significantly improved, and SOD, CAT are respectively increased 56.48U/mL, 23.89U/mL in CH126 group serum, with model
Group is compared to difference extremely significantly (P<0.01)；GSH-Px levels bring up to 91.24nmol/mL in CH126 groups serum at the end of experiment
(P<0.05)；MDA contents are significantly reduced in serum.During result shows that Lactobacillus plantarum CH126 can significantly improve mice serum
Superoxide dismutase, catalase and activity of glutathione peroxidase, suppress MDA vigor, show obvious
Oxidation resistance.
Influences of the Lactobacillus plantarum CH126 of table 9 to Antioxidant Indexes in diabetes B mice serum
Note：Compare with model group, * has significant difference (P ＜ 0.05), * * have pole significant difference (P ＜ 0.01).
D-ALPHA-Hydroxypropionic acid, free fatty, endotoxic testing result are shown in Table 10 in serum.The body Portugal that diabetes B causes
Grape sugar, protein and disorders of lipid metabolism, cause substantial amounts of D-ALPHA-Hydroxypropionic acid, free fatty, endotoxin to enter blood, and influence is normal
Physiological metabolism.The intake of Lactobacillus plantarum CH126 can be different degrees of improvement serum in D-ALPHA-Hydroxypropionic acid, free fatty, interior
Content of toxins, experiment terminates D-ALPHA-Hydroxypropionic acid in rear CH126 groups mice serum, free fatty acid content and obviously drops to 2.27 μm of ol/
ML, 689.27 μ g/L, endotoxin content are reduced to 71.34EU/L (P<0.05).Result shows that Lactobacillus plantarum CH126 may
By adjusting diabetes B mouse body lipid metabolic disorder, suppress D-ALPHA-Hydroxypropionic acid, free fatty, endotoxin and largely enter blood
Liquid.
The Lactobacillus plantarum CH126 of table 10 to diabetes B D-ALPHA-Hydroxypropionic acid, free fatty, endotoxin content influence
| Group | D-Lactate(μmol/mL) | FFA(μg/L) | ET(EU/L) |
| Blank control group | 1.96±0.23 | 567.14±6.48 | 59.47±4.92 |
| Model group | 3.05±0.47 | 722.48±5.34 | 82.16±5.84 |
| Melbine group | 2.11±0.26* | 665.38±4.67 | 64.55±7.69** |
| CH126 groups | 2.27±0.38 | 689.27±4.59 | 71.34±6.60* |
SEQUENCE LISTING
<110>Jilin Academy of Agricultural Science
<120>Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared
<130> GNCYX170653
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 1504
<212> DNA
<213>Lactobacillus plantarum（Lactobacillus plantarum）
<400> 1
cgatctcgct cttgttacga cttcacccta atcatctgtc ccaccttagg cggctggttc 60
ctaaaaggtt accccaccga ctttgggtgt tacaaactct catggtgtga cgggcggtgt 120
gtacaaggcc cgggaacgta ttcaccgcgg catgctgatc cgcgattact agcgattccg 180
acttcatgta ggcgagttgc agcctacaat ccgaactgag aatggcttta agagattagc 240
ttactctcgc gagttcgcaa ctcgttgtac catccattgt agcacgtgtg tagcccaggt 300
cataaggggc atgatgattt gacgtcatcc ccaccttcct ccggtttgtc accggcagtc 360
tcaccagagt gcccaactta atgctggcaa ctgataataa gggttgcgct cgttgcggca 420
cttaacccca cactctcacg acacgagctg acgacaacca tgcaccccct gtatccatgt 480
ccccgaaggg aacgtctaat ctcttagatt tgcatagtat gtcaagacct ggtaaggttc 540
ttcgcgtagc ttcgaattaa accacatgct ccaccgcttg tgcgggcccc cgtcaattcc 600
tttgagtttc agccttgcgg ccgtactccc caggcggaat gcttaatgcg ttagctgcag 660
cactgaaggg cggaaaccct ccaacactta gcattcatcg tttacggtat ggactaccag 720
ggtatctaat cctgtttgct acccatactt tcgagcctca gcgtcagtta cagaccagac 780
agccgccttc gccactggtg ttcttccata tatctacgca tttcaccgct acacatggag 840
ttccactgtc ctcttctgca ctcaagtttc ccagtttccg atgcacttct tcggttgagc 900
cgaaggcttt cacatcagac ttaaaaaacc gcctgcgctc gctttacgcc caataaatcc 960
ggacaacgct tgccacctac gtattaccgc ggctgctggc acgtagttag ccgtggcttt 1020
ctggttaaat accgtcaata cctgaacagt tactcctcag atatgttctt ctttaacaac 1080
agagttttac ggagccgaaa cccttcttca ctcacgcggc gttgctccat cagactttcg 1140
tccattgtgg aagattccct actgctgcct cccgtaggag tttgggccgt gtctcagtcc 1200
caatgtggcc gattaccctc tcaggtcggc tacgtatcat tgccatggtg agccgttacc 1260
ccaccatcta gctaatacgc cgcgggacca tccaaaagtg atagccgaag ccatctttca 1320
agctcggacc atgcggtcca agttgttatg cggtattagc atctgtttcc aggtgttatc 1380
ccccgcttct gggcaggttt cccacgtgtt actcaccagt tcgccactca ctcaaatgta 1440
aatcatgatg caagcaccaa tcaataccag agttcgttcg acttgcatgt attaggcagg 1500
gccg 1504
Claims (10)
1. Lactobacillus plantarum (Lactobacillus plantarum) CH126, its deposit number is CGMCC NO.13228.
2. application of the Lactobacillus plantarum described in claim 1 in product is prepared.
3. application as claimed in claim 2, it is characterised in that：The product is food, health products or medicine.
4. application as claimed in claim 2 or claim 3, it is characterised in that：The function of the product is in following (a1) to (a31)
At least one：
(a1) hypoglycemic and/or reducing blood lipid；
(a2) blood-sugar content in serum is reduced；
(a3) lipids contents in serum are reduced；
(a4) total cholesterol level in serum is reduced；
(a5) content of triglyceride in serum is reduced；
(a6) fasting blood sugar is reduced；
(a7) oxidation resistance is increased；
(a8) content and/or activity of the superoxide dismutase in serum are increased；
(a9) content and/or activity of the catalase in serum are increased；
(a10) content and/or activity of the glutathione peroxidase in serum are increased；
(a11) content and/or activity of the MDA in serum are reduced；
(a12) disorders of lipid metabolism is improved；
(a13) the D-ALPHA-Hydroxypropionic acid content in serum is reduced；
(a14) free fatty acid content in serum is reduced；
(a15) endotoxin content in serum is reduced；
(a16) treat and/or prevention diabetes；
(a17) blood-sugar content in Diabetes Mellitus is reduced；
(a18) lipids contents in Diabetes Mellitus are reduced；
(a19) total cholesterol level in Diabetes Mellitus is reduced；
(a20) content of triglyceride in Diabetes Mellitus is reduced；
(a21) fasting blood sugar of diabetic is reduced；
(a22) insulin content in Diabetes Mellitus is raised；
(a23) content and/or activity of the superoxide dismutase in Diabetes Mellitus are increased；
(a24) content and/or activity of the catalase in Diabetes Mellitus are increased；
(a25) content and/or activity of the glutathione peroxidase in Diabetes Mellitus are increased；
(a26) content and/or activity of the MDA in Diabetes Mellitus are reduced；
(a27) disorders of lipid metabolism of diabetic is improved；
(a28) the D-ALPHA-Hydroxypropionic acid content in Diabetes Mellitus is reduced；
(a29) free fatty acid content in Diabetes Mellitus is reduced；
(a30) endotoxin content in Diabetes Mellitus is reduced；
(a31) hyperlipidemic conditions of diabetic are improved.
5. application as claimed in claim 4, it is characterised in that：The diabetes are diabetes B.
6. a kind of product, its active component is Lactobacillus plantarum described in claim 1.
7. a kind of product, its active component plant described in the fermentate or claim 1 of Lactobacillus plantarum described in claim 1
The extract of the fermentate of lactobacillus.
8. product as claimed in claims 6 or 7, it is characterised in that：The product is food, health products or medicine.
9. the product as described in claim 6 or 7 or 8, it is characterised in that：The function of the product is following (a1) to (a31)
In at least one：
(a1) hypoglycemic and/or reducing blood lipid；
(a2) blood-sugar content in serum is reduced；
(a3) lipids contents in serum are reduced；
(a4) total cholesterol level in serum is reduced；
(a5) content of triglyceride in serum is reduced；
(a6) fasting blood sugar is reduced；
(a7) oxidation resistance is increased；
(a8) content and/or activity of the superoxide dismutase in serum are increased；
(a9) content and/or activity of the catalase in serum are increased；
(a10) content and/or activity of the glutathione peroxidase in serum are increased；
(a11) content and/or activity of the MDA in serum are reduced；
(a12) disorders of lipid metabolism is improved；
(a13) the D-ALPHA-Hydroxypropionic acid content in serum is reduced；
(a14) free fatty acid content in serum is reduced；
(a15) endotoxin content in serum is reduced；
(a16) treat and/or prevention diabetes；
(a17) blood-sugar content in Diabetes Mellitus is reduced；
(a18) lipids contents in Diabetes Mellitus are reduced；
(a19) total cholesterol level in Diabetes Mellitus is reduced；
(a20) content of triglyceride in Diabetes Mellitus is reduced；
(a21) fasting blood sugar of diabetic is reduced；
(a22) insulin content in Diabetes Mellitus is raised；
(a23) content and/or activity of the superoxide dismutase in Diabetes Mellitus are increased；
(a24) content and/or activity of the catalase in Diabetes Mellitus are increased；
(a25) content and/or activity of the glutathione peroxidase in Diabetes Mellitus are increased；
(a26) content and/or activity of the MDA in Diabetes Mellitus are reduced；
(a27) disorders of lipid metabolism of diabetic is improved；
(a28) the D-ALPHA-Hydroxypropionic acid content in Diabetes Mellitus is reduced；
(a29) free fatty acid content in Diabetes Mellitus is reduced；
(a30) endotoxin content in Diabetes Mellitus is reduced；
(a31) hyperlipidemic conditions of diabetic are improved.
10. product as claimed in claim 9, it is characterised in that：The diabetes are diabetes B.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710228755.0A CN106834196A (en) | 2017-04-10 | 2017-04-10 | Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710228755.0A CN106834196A (en) | 2017-04-10 | 2017-04-10 | Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106834196A true CN106834196A (en) | 2017-06-13 |
Family
ID=59147462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710228755.0A Pending CN106834196A (en) | 2017-04-10 | 2017-04-10 | Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106834196A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475160A (en) * | 2017-09-20 | 2017-12-15 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum and its application with dual hypoglycemic target spot |
| CN108085285A (en) * | 2018-01-25 | 2018-05-29 | 吉林省命之元生物科技有限公司 | One DM-50 plants of lactobacillus plantarum and its application |
| CN108570436A (en) * | 2017-12-14 | 2018-09-25 | 浙江大学 | Lactobacillus plantarum ZJUF T17 and its application |
| CN108641988A (en) * | 2018-06-15 | 2018-10-12 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and its application in alleviating non-alcoholic fatty liver disease |
| CN109364102A (en) * | 2018-12-29 | 2019-02-22 | 重庆第二师范学院 | Application of the lactobacillus plantarum CQPC03 in the food or drug of preparation prevention diabetes |
| CN109645490A (en) * | 2018-12-29 | 2019-04-19 | 重庆第二师范学院 | Application of the lactobacillus plantarum CQPC02 in the food or drug of preparation prevention diabetes |
| CN109758494A (en) * | 2017-11-10 | 2019-05-17 | 大江生医股份有限公司 | Mung bean shell tunning and its application |
| CN110964659A (en) * | 2019-08-02 | 2020-04-07 | 四川大学 | Lactobacillus plantarum with blood sugar reducing effect, screening method thereof, application medicament and food |
| CN113308421A (en) * | 2021-07-30 | 2021-08-27 | 北京量化健康科技有限公司 | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome |
| CN114259508A (en) * | 2022-01-12 | 2022-04-01 | 安徽斯普瑞生物科技有限公司 | Application of ganoderma lucidum strain SS30 in preparation of product for treating or preventing diabetes |
| CN114437997A (en) * | 2022-04-07 | 2022-05-06 | 山东向日葵生物工程有限公司 | Lactobacillus plantarum SF-L38 and application thereof in preparation of blood sugar control product |
| CN115025134A (en) * | 2022-07-01 | 2022-09-09 | 南京盛德生物科技研究院有限公司 | Composition containing lactobacillus plantarum and preparation method and application thereof |
| CN115135749A (en) * | 2019-12-31 | 2022-09-30 | Gi生物群系公司 | Lactobacillus plantarum strain and composition for preventing or treating metabolic diseases containing the same |
| CN117535194A (en) * | 2023-11-16 | 2024-02-09 | 黑龙江禾家福农业科技有限公司 | Lactobacillus plantarum |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105105145A (en) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat |
| CN105567586A (en) * | 2015-12-21 | 2016-05-11 | 南昌大学 | Lactobacillus plantarum having anti-diabetic function and application thereof |
| CN106074623A (en) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | Lactobacillus plantarum application in preparation has the product of hepatoprotective function |
-
2017
- 2017-04-10 CN CN201710228755.0A patent/CN106834196A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105105145A (en) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat |
| CN105567586A (en) * | 2015-12-21 | 2016-05-11 | 南昌大学 | Lactobacillus plantarum having anti-diabetic function and application thereof |
| CN106074623A (en) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | Lactobacillus plantarum application in preparation has the product of hepatoprotective function |
Non-Patent Citations (8)
| Title |
|---|
| 余元勋等主编: "《中国分子糖尿病学》", 30 April 2016, 安徽科学技术出版社 * |
| 李永生等主编: "《肿瘤急症学》", 30 September 2009, 科学技术文献出版社 * |
| 杜智等主编: "《临床代谢组学》", 31 May 2013, 天津科技翻译出版有限公司 * |
| 沈业寿主编: "《药用真菌桑黄菌的研究》", 30 June 2014, 中国科学技术大学出版社 * |
| 温贺等: "植物乳杆菌Sc52益生特性评价及其在降血糖产品中的应用", 《食品科学》 * |
| 熊强等: "植物乳杆菌的功能评价", 《生物加工过程》 * |
| 靳志强等: "植物乳杆菌耐酸耐胆盐的体外试验及其降胆固醇作用", 《中国食品学报》 * |
| 马爽等: "益生性植物乳杆菌的体外抗氧化活性研究", 《中国乳品工业》 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475160A (en) * | 2017-09-20 | 2017-12-15 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum and its application with dual hypoglycemic target spot |
| CN107475160B (en) * | 2017-09-20 | 2020-10-23 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum with dual hypoglycemic targets and application thereof |
| CN109758494A (en) * | 2017-11-10 | 2019-05-17 | 大江生医股份有限公司 | Mung bean shell tunning and its application |
| CN108570436B (en) * | 2017-12-14 | 2020-08-04 | 浙江大学 | Lactobacillus plantarum ZJUF T17 and application thereof |
| CN108570436A (en) * | 2017-12-14 | 2018-09-25 | 浙江大学 | Lactobacillus plantarum ZJUF T17 and its application |
| CN108085285A (en) * | 2018-01-25 | 2018-05-29 | 吉林省命之元生物科技有限公司 | One DM-50 plants of lactobacillus plantarum and its application |
| CN108641988A (en) * | 2018-06-15 | 2018-10-12 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and its application in alleviating non-alcoholic fatty liver disease |
| CN108641988B (en) * | 2018-06-15 | 2021-09-21 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and application thereof in relieving non-alcoholic fatty liver disease |
| CN109364102A (en) * | 2018-12-29 | 2019-02-22 | 重庆第二师范学院 | Application of the lactobacillus plantarum CQPC03 in the food or drug of preparation prevention diabetes |
| CN109645490A (en) * | 2018-12-29 | 2019-04-19 | 重庆第二师范学院 | Application of the lactobacillus plantarum CQPC02 in the food or drug of preparation prevention diabetes |
| CN110964659A (en) * | 2019-08-02 | 2020-04-07 | 四川大学 | Lactobacillus plantarum with blood sugar reducing effect, screening method thereof, application medicament and food |
| CN115135749A (en) * | 2019-12-31 | 2022-09-30 | Gi生物群系公司 | Lactobacillus plantarum strain and composition for preventing or treating metabolic diseases containing the same |
| CN113308421A (en) * | 2021-07-30 | 2021-08-27 | 北京量化健康科技有限公司 | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome |
| CN113308421B (en) * | 2021-07-30 | 2022-01-07 | 北京量化健康科技有限公司 | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome |
| CN114259508A (en) * | 2022-01-12 | 2022-04-01 | 安徽斯普瑞生物科技有限公司 | Application of ganoderma lucidum strain SS30 in preparation of product for treating or preventing diabetes |
| CN114437997A (en) * | 2022-04-07 | 2022-05-06 | 山东向日葵生物工程有限公司 | Lactobacillus plantarum SF-L38 and application thereof in preparation of blood sugar control product |
| CN114437997B (en) * | 2022-04-07 | 2022-06-10 | 山东向日葵生物工程有限公司 | Lactobacillus plantarum SF-L38 and application thereof in preparation of blood sugar control product |
| CN115025134A (en) * | 2022-07-01 | 2022-09-09 | 南京盛德生物科技研究院有限公司 | Composition containing lactobacillus plantarum and preparation method and application thereof |
| CN117535194A (en) * | 2023-11-16 | 2024-02-09 | 黑龙江禾家福农业科技有限公司 | Lactobacillus plantarum |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106834196A (en) | Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared | |
| CN110604749B (en) | Bifidobacterium animalis A12 and its application in controlling diabetes or hyperlipidemia, especially weight gain or obesity | |
| CN105105145A (en) | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat | |
| CN108048368B (en) | One UA-416 plants of lactobacillus plantarum and its application | |
| CN113308421B (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| CN110150669A (en) | A kind of probiotic composition and its application suitable for patients with diabetes mellitus | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN113322216B (en) | Lactobacillus paracasei B111H and application thereof in metabolic syndrome | |
| CN107550942A (en) | Application of the secondary bacteroid in metabolic disease is treated and prevented | |
| CN105053202A (en) | Preparation method of high-quality fermented camel milk with function of auxiliarily lowering blood sugar | |
| CN115786207A (en) | Lactobacillus salivarius and application thereof in preparation of medicines for treating and/or preventing diabetes | |
| CN107412272A (en) | Application of the Lactobacillus plantarum in gut barrier injury is prevented | |
| CN111304134B (en) | Lactobacillus plantarum capable of effectively relieving diabetes | |
| CN106389478A (en) | Applications of Bacteroides fragilis in treatment and/or prevention of obesity or diabetes mellitus | |
| CN112831444A (en) | Lactobacillus rhamnosus LR2Y and application thereof | |
| CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
| CN110638841B (en) | Probiotics and prebiotics composite preparation, preparation method and application thereof | |
| CN107468835A (en) | The composition of microbial fermentation cattail pollen and its application | |
| CN115044507B (en) | Microbial composition for treating and/or preventing abnormal glycolipid metabolism and application thereof | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| CN109136151B (en) | Compound lactobacillus plantarum preparation with blood sugar reducing function and application thereof | |
| CN103263484B (en) | A kind of fermentation process of bran of Radix Et Rhizoma Fagopyri Tatarici and tunning thereof | |
| CN112043723B (en) | Application of bacillus amyloliquefaciens exopolysaccharide | |
| EP4223867A1 (en) | Bacillus coagulans having blood glucose reduction efficacy, and application thereof | |
| CN112385846B (en) | Application of bacillus coagulans in preparation of anti-alcoholic composition and edible product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |
|
| RJ01 | Rejection of invention patent application after publication |